Wolfgang Miesbach: One-Time CRISPR Therapy Reduces Hereditary Angioedema Attacks by 87%
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article by Danny M. Cohn et al, published in NEJM, adding:
”One-Time CRISPR Infusion Cuts HAE Attacks by 87%.
In the phase 3 HAELO trial, a single 50 mg IV infusion of lonvoguran ziclumeran (lonvo‑z) — an in vivo CRISPR-based therapy targeting KLKB1 — led to a profound and durable reduction of hereditary angioedema (HAE) attacks.
KLKB1 encodes plasma prekallikrein; by introducing precise edits in hepatocyte DNA, lonvo‑z durably reduces prekallikrein production in the liver, rebalancing the kallikrein–kinin pathway and lowering bradykinin-driven angioedema risk.
Dosing
- One-time, 50 mg intravenous infusion (no repeat dosing through week 28)
- Long-term prophylaxis was washed out and not permitted during weeks 5–28
Efficacy (weeks 5–28)
- Mean monthly attack rate: 0.26 with lonvo‑z vs 2.10 with placebo (−87%; P<0.001)
- 62% of patients on lonvo‑z were completely attack‑free without long-term prophylaxis (vs 11% with placebo)
- On‑demand–treated and moderate/severe attacks were reduced by ~90%; AE‑QoL improved by −23.5 points, well above the minimal clinically important difference
Safety
AEs in 92% (lonvo‑z) vs 86% (placebo), all grade 1–2 in the lonvo‑z arm; no serious or grade ≥3 events reported with lonvo‑z.
Most frequent events: infusion‑related reactions (62%), headache, fatigue, back pain, upper respiratory tract infection; liver enzyme elevations were mild, transient, and self‑limiting.”
Title: Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
Authors: Danny M. Cohn, Padmalal Gurugama, Hilary J. Longhurst, Emel Aygören-Pürsün, Timothy J. Craig, Henriette Farkas, Joshua Jacobs, William R. Lumry, Markus Magerl, Jonny Peter, Marc A. Riedl, David Maag, Adele Golden, Mrinal Y. Shah, Andrea Sutherland, Catherine R. Miller, Ahmed M. Abdelhady, Yuanxin Xu, James S. Butler, David Lebwohl, John Leonard, Aleena Banerji

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome